Novartis CEO Vas Narasimhan expressed significant concerns regarding the U.S. drug pricing policy under President Trump, describing it as a “very difficult situation” for both drugmakers and patients. Speaking to CNBC, Narasimhan emphasized that the long-term implications of the policy could lead to delayed access to innovative medicines in European and Japanese markets if governments do not adjust their reward systems for pharmaceutical innovation.
This warning highlights potential disruptions in the pharmaceutical sector, which could affect stock performance for companies reliant on timely drug approvals and market access. If novel therapies face entry delays, it could impact revenue forecasts and investor sentiment, particularly for firms like Novartis that are heavily invested in research and development.
Market professionals should monitor the evolving landscape of drug pricing policies and their implications on global market access, as these developments could influence investment strategies and portfolio allocations in the healthcare sector.
Source: cnbc.com